Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Latest Biotechnology and TG Therapeutics, Inc., Recursion Pharmaceuticals, Inc. Stock News

As of March 6, 2026, TG Therapeutics, Inc. had a $4.3 billion market capitalization, compared to the Biotechnology median of $273.7 million. TG Therapeutics, Inc.’s stock is down 1.8% in 2026, down 2.7% in the previous five trading days and down 16.63% in the past year.

Currently, TG Therapeutics, Inc.’s price-earnings ratio is 10.6. TG Therapeutics, Inc.’s trailing 12-month revenue is $616.3 million with a 72.6% net profit margin. Year-over-year quarterly sales growth most recently was 78.0%. Analysts expect adjusted earnings to reach $1.256 per share for the current fiscal year. TG Therapeutics, Inc. does not currently pay a dividend.

As of March 6, 2026, Recursion Pharmaceuticals, Inc. had a $1.8 billion market cap, putting it in the 53rd percentile of all stocks. Recursion Pharmaceuticals, Inc.’s stock is down 15.4% in 2026, down 5.7% in the previous five trading days and down 47.42% in the past year.

Currently, Recursion Pharmaceuticals, Inc. does not have a price-earnings ratio. Recursion Pharmaceuticals, Inc.’s trailing 12-month revenue is $74.7 million with a -863.4% net profit margin. Year-over-year quarterly sales growth most recently was 688.9%. Analysts expect adjusted earnings to reach $-0.986 per share for the current fiscal year. Recursion Pharmaceuticals, Inc. does not currently pay a dividend.

How We Compare TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. Stock Value Grades

Company	Ticker	Value
TG Therapeutics, Inc.	TGTX	D
Recursion Pharmaceuticals, Inc.	RXRX	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

TG Therapeutics, Inc. has a Value Score of 28, which is Expensive. Recursion Pharmaceuticals, Inc. has a Value Score of 11, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. is the better investment when it comes to value.

TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. Growth Grades

Company	Ticker	Growth
TG Therapeutics, Inc.	TGTX	F
Recursion Pharmaceuticals, Inc.	RXRX	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

TG Therapeutics, Inc. has a Growth Score of 18, which is Very Weak. Recursion Pharmaceuticals, Inc. has a Growth Score of 28, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. is the better investment when it comes to sustainable growth.

TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc.’s Momentum Grades

Company	Ticker	Momentum
TG Therapeutics, Inc.	TGTX	D
Recursion Pharmaceuticals, Inc.	RXRX	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

TG Therapeutics, Inc. has a Momentum Score of 27, which is Weak. Recursion Pharmaceuticals, Inc. has a Momentum Score of 11, which is Very Weak.

The Momentum Stock Winner: No Clear Winner

Neither TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. is the better investment when it comes to momentum.

Other TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. Grades

In addition to Value, Growth and Momentum, A+ Investor also provides grades for Estimate Revisions and Quality.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, TG Therapeutics, Inc., Recursion Pharmaceuticals or Inc. Stock?

Overall, TG Therapeutics, Inc. stock has a Value Score of 28, Growth Score of 18 and Momentum Score of 27.

Recursion Pharmaceuticals, Inc. stock has a Value Score of 11, Growth Score of 28 and Momentum Score of 11.

Comparing TG Therapeutics, Inc., Recursion Pharmaceuticals and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.